Revolution Medicines (RVMD) Assets (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Assets of $2.3 billion for Q1 2026, down 4.72% year-over-year from $2.4 billion in Q1 2025, and down 4.28% quarter-over-quarter from $2.4 billion in Q4 2025.
Revolution Medicines (RVMD) Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Assets history runs 8 years deep, the most recent figure standing at $2.3 billion for Q1 2026.
- In Q1 2026, Assets fell 4.72% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 4.72% YoY), while the FY2025 annual figure was $2.4 billion, down 7.97% from the prior year.
- Assets for Q1 2026 stood at $2.3 billion, down from $2.4 billion in the prior quarter.
- The five-year high for Assets was $2.6 billion in Q4 2024, with the low at $55.9 million in Q2 2024.
- The 5-year median for Assets is $1.8 billion (2024), against an average of $1.5 billion.
- The sharpest annual moves came in 2024 and 2025: Assets plunged 94.79% in 2024, then jumped 4246.28% in 2025.
- Revolution Medicines' Assets stood at $811.9 million in 2022, then soared by 153.93% to $2.1 billion in 2023, then advanced by 24.09% to $2.6 billion in 2024, then retreated by 7.97% to $2.4 billion in 2025, then slipped by 4.28% to $2.3 billion in 2026.
- Business Quant data shows RVMD's Assets at $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.32 Bn |
| Mar 31, 2026 | 2.25 Bn |
| Dec 31, 2025 | 2.35 Bn |
| Sep 30, 2025 | 2.25 Bn |
| Jun 30, 2025 | 2.43 Bn |
| Mar 31, 2025 | 2.37 Bn |
| Dec 31, 2024 | 2.56 Bn |
| Sep 30, 2024 | 1.76 Bn |
| Jun 30, 2024 | 55.90 Mn |
| Mar 31, 2024 | 1.91 Bn |
| Dec 31, 2023 | 2.06 Bn |
| Sep 30, 2023 | 984.23 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 811.93 Mn |
| Sep 30, 2022 | 825.91 Mn |
| Jun 30, 2022 | 632.80 Mn |
| Mar 31, 2022 | 682.77 Mn |
| Dec 31, 2021 | 737.99 Mn |
| Sep 30, 2021 | 734.98 Mn |